Multiple Sclerosis-related Uveitis: Does MS Treatment Affect Uveitis Course?

REFERENCES

• Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med. 2002;53:285–302.
   PubMed Web of Science ®Google Scholar
• Jersild C, Svejgaard A, Fog T. HL-A antigens and multiple sclerosis. Lancet. 1972;1:1240–1241.
   PubMed Web of Science ®Google Scholar
• Weiner HL. A 21 point unifying hypothesis on the etiology and treatment of multiple sclerosis. Can J Neurol Sci. 1998;25:93–101.
   PubMed Web of Science ®Google Scholar
• Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2:119–125.
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45:1277–1285.
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498–1504.
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45:1268–1276.
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.
   PubMed Web of Science ®Google Scholar
• Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol. 2011;10:1026–1034.
   PubMed Web of Science ®Google Scholar
• Le Scanff J, Sève P, Renoux C, et al. Uveitis associated with multiple sclerosis. Mult Scler. 2008;14:415–417.
   PubMed Web of Science ®Google Scholar
• Maca SM, Scharitzer M, Barisani-Asenbauer T. Uveitis and neurologic diseases: an often overlooked relationship. Wien Klin Wochenschr. 2006;118(9–10):273–279.
   PubMed Web of Science ®Google Scholar
• Schmidt S, Wessels L, Augustin A, et al. Patients with multiple sclerosis and concomitant uveitis/periphlebitis retinae are not distinct from those without intraocular inflammation. J Neurol Sci. 2001;187(1–2):49–53.
   PubMed Web of Science ®Google Scholar
• Rothova A. Medical treatment of cystoid macular edema. Ocul Immunol Inflamm. 2002;10:239–246.
   PubMed Web of Science ®Google Scholar
• Mackensen F, Jakob E, Springer C, et al. Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol. 2013;156:478–486.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol. 2005;58:840–846.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452.
   PubMed Web of Science ®Google Scholar
• Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. 1987;103:234–235.
   PubMed Web of Science ®Google Scholar
• Biousse V, Trichet C, Bloch-Michel E, et al. Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology. 1999;52:179–181.
   PubMed Web of Science ®Google Scholar
• Meisler DM, Tomsak RL, Khoury S, et al. Anterior uveitis and multiple sclerosis. Cleve Clin J Med. 1989;56:535–538.
   PubMed Web of Science ®Google Scholar
• Lim JI, Tessler HH, Goodwin JA. Anterior granulomatous uveitis in patients with multiple sclerosis. Ophthalmology. 1991;98:142–145.
   PubMed Web of Science ®Google Scholar
• Zein G, Berta A, Foster CS. Multiple sclerosis-associated uveitis. Ocul Immunol Inflamm. 2004;12:137–142.
   PubMed Web of Science ®Google Scholar
• Rothova A, Buitenhuis HJ, Meenken C, et al. Uveitis and systemic disease. Br J Ophthalmol. 1992;76:137–141.
   PubMed Web of Science ®Google Scholar
• Prieto JF, Dios E, Gutierrez JM, et al. Pars planitis: epidemiology, treatment, and association with multiple sclerosis. Ocul Immunol Inflamm. 2001:9:93–102.
   Web of Science ®Google Scholar
• Malinowski SM, Pulido JS, Goeken NE, et al. The association of HLA-B8, B51, DR2, and multiple sclerosis in pars planitis. Ophthalmology. 1993;100:1199–1205.
   PubMed Web of Science ®Google Scholar
• Raja SC, Jabs DA, Dunn JP, et al. Pars planitis: clinical features and class II HLA associations. Ophthalmology. 1999;106:594–599.
   PubMed Web of Science ®Google Scholar
• Graham EM, Stanford MR, Sanders MD, et al. A point prevalence study of 150 patients with idiopathic retinal vasculitis: 1. Diagnostic value of ophthalmological features. Br J Ophthalmol. 1989;73:714–721.
   PubMed Web of Science ®Google Scholar
• Tang WM, Pulido JS, Eckels DD, et al. The association of HLA-DR15 and intermediate uveitis. Am J Ophthalmol. 1997;123:70–75.
   PubMed Web of Science ®Google Scholar
• Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol. 1992;10:153–187.
   PubMed Web of Science ®Google Scholar
• Hanes GP, Staugaitis SM, Meisler DM, et al. Isolated granulomatous uveitis presenting twenty-two years before multiple sclerosis. J Neuro-Ophthalmol. 2004;24:346–347.
   PubMed Web of Science ®Google Scholar
• Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370:389–397.
   PubMed Web of Science ®Google Scholar
• Becker MD, Heiligenhaus A, Hudde T, et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol. 2005;89:1254–1257.
   PubMed Web of Science ®Google Scholar
• Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254–260.
   PubMed Web of Science ®Google Scholar